Sold as Vistide. Every FDA application for this active ingredient: 1 branded and 2 generic.
As of Nov 14, 2026, FDA lists 3 applications for Cidofovir (sold as Vistide), first approved Jun 26, 1996, with 1 new use approved and 0 published complete response letters.
| Cidofovir | Part B | $577K | -27% | 276 |
| Cidofovir | Part D | $98K | -41% | 35 |
| A Phase 3 Trial to Compare IV BCV Versus IV CDV for Treatment of Adenovirus Infection After Allo-HCTAdenovirus Infections · SymBio Pharmaceuticals | Phase 3 | Recruiting | Feb 4, 2026 |
| A Study of LIVTENCITY (Maribavir) in Adults With Cytomegalovirus (CMV) Infection After Transplantation in South KoreaCytomegalovirus (CMV) · Takeda | — | Recruiting | Aug 15, 2024 |
| Cidofovir Versus Best Supportive Care for Hemorrhagic CystitisTransplantation Infection · M.D. Anderson Cancer Center | Phase 2 | Active, not recruiting | Feb 14, 2011 |
| Jun 26, 1996 | VistideNDA 20638 · New molecular entity | Gilead Sciences Inc | 4 | Discontinued |
| Jun 27, 2012 | CidofovirANDA 201276 | Mylan Institutional | 0 | Marketed |
| Jul 26, 2012 | CidofovirANDA 202501 | Avet Lifesciences | 1 | Marketed |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA
